Adding Bevacizumab to Standard Treatment Improves Overall Survival in Patients with Malignant Pleural Mesothelioma
DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.
Results From Phase III Trials of Anamorelin in Advanced Non-Small Cell Lung Cancer Patients with Cachexia: ROMANA 1 and 2
DENVER, Colo. — Two Phase III studies with anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain lung cancer patients. Results from the ROMANA 1 and ROMANA 2 Phase III trial of anamorelin were presented today in Denver, Colo. at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).
Impact of Time to Drug Approval on Potential Years of Life Lost: The Compelling Need for Improved Trial and Regulatory Efficiency
DENVER, Colo. — Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the U.S. and 260 life-years worldwide, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). Dr. David Stewart, Head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, presented data on how the regulatory process of new therapies slows progress by increasing drug developments costs and by producing speed bumps that delay approval of useful drugs. This process also increases resources required to document that other agents are ineffective.
DENVER, Colo. — The International Association for the Study of Lung Cancer (IASLC) today issued a new statement on Tobacco Control and Smoking Cessation at the 16th World Conference on Lung Cancer (WCLC) in Denver. The statement calls for higher taxes on tobacco products, comprehensive advertising and promotion bans of all tobacco products and product regulation including pack warnings.
DENVER, Colo. – The International Association for the Study of Lung Cancer’s (IASLC) Strategic Screening Advisory Committee will hold the Third CT Screening Workshop on Saturday, Sept. 5 at 9 a.m. at the Colorado Convention Center, Rooms 708+710+712, prior to the official opening of the 16th Annual World Conference on Lung Cancer (WCLC). International leaders in computed tomography (CT) screening from across the world, including Japan, Australia, Canada, Europe and the U.S., are set to participate.
Speaking in an interview with Oncology Nursing News, Dr. Fred R. Hirsch, CEO of IASLC, Professor of Medicine and Pathology at the University of Colorado, discusses the importance of combination therapies in the fight against lung cancer.